Last updated: April 24, 2026
What does Finland patent FI3263110 cover, and how does it sit in the drug patent landscape?
What is FI3263110 (scope, procedural posture, and claim focus)?
FI3263110 is a Finnish utility patent application/publication tied to a specific drug invention. The patent is associated with a medicinal substance/combination and related therapeutic use, with claim scope structured around:
- Compound or composition (active ingredient and/or pharmaceutically acceptable composition)
- Method-of-treatment (therapeutic indication(s) and dosing regimens)
- Specific embodiments that define how the product is made or used (selected substituents, salts/solvates, and/or patient populations)
Claim scope is typically anchored to:
1) Defined chemical entities (or pharmaceutical compositions)
2) Defined clinical use (indication and patient treatment method)
3) Defined formulation or dosing parameters when the application uses product-by-process or regimen claims
What are the claim elements that drive enforceable scope?
Across FI filings in this category, the enforceable claim core generally clusters into four groups:
| Claim cluster |
What it covers |
What typically determines infringement |
| Compound/composition |
Active ingredient entity, salt/solvate, excipient system |
Use/sale of the specific defined entity or composition within the claim parameters |
| Medical use (indication) |
Therapeutic use for a named disease/condition |
Use of the drug for the specific indication in the claim’s permitted medical context |
| Method of treatment |
Steps and dosing regimen |
Administration or prescribing consistent with the claimed regimen |
| Dependent embodiments |
Specific substitutions, dose ranges, formulation options |
Whether the accused product falls inside the narrow dependent boundaries |
Practical reading: the claims that matter most for commercial freedom to operate (FTO) are (a) the independent composition/compound claim and (b) the independent medical-use and/or method-of-treatment claim. Dependent claims often decide whether design-arounds remain viable.
How long does protection likely run in Finland?
For Finnish utility patents, the standard term is 20 years from the filing date, subject to national validity and any term adjustments/extensions (and separate national rules for supplementary protection certificates where applicable). In the FI context, term strategy often depends on:
- Filing date of the underlying application family
- Whether the Finnish grant occurs and when
- Whether SPCs are pursued for the underlying active ingredient in Finland
Because FI3263110 is a single numbered national publication, landscape outcomes for the Finland market depend on the entire family (priority, other jurisdictions, and whether SPCs are in play), not only the FI publication number.
How does FI3263110 compare with other Finland drug patent coverage (landscape mapping)?
What patterns dominate Finland drug patent estates around this type of FI filing?
In Finland, drug patent estates typically show three layers:
1) Early invention layer: composition/compound coverage (core chemical and product)
2) Clinical layer: specific indications, patient subsets, or treatment protocols
3) Life-cycle layer: formulation, salt/solvate variants, dosing frequency, or combination refinement
FI3263110 fits the typical Finland structure where the claim set spans both the drug entity/composition and therapeutic use.
Which other claim types usually appear in the same family and affect FTO?
For an FI drug application like FI3263110, related family members commonly include:
- Broader Markush-type composition claims (chemical scope first, then dependent narrowing)
- Second-medical-use claims (new indication, new patient group, or revised clinical end point)
- Formulation claims (delivery system, excipient matrix, particle size or release profile)
- Combination therapy claims (co-administration with a second active ingredient)
- Process/product-by-process claims (manufacturing method that defines the product attributes)
From a landscape standpoint, this matters because freedom-to-operate can fail even if a generic candidate avoids the “compound” claim by falling inside the family’s medical use or dosing regimen claims.
Where is FI3263110 likely strongest in the chain of enforcement (composition vs use)?
Does FI3263110 primarily protect the product or the treatment?
The strongest and most commercially relevant scope is usually:
- Composition/compound protection for the active ingredient entity and closely defined salts/solvates
- Method-of-treatment / medical use protection for specific indications and dosing regimens
In practice, the Finland market impact depends on whether the drug is launched under the same indication covered by the medical-use claims and whether local prescribing aligns with the claimed regimen.
What is the likely breadth of independent claims?
For FI utility applications, breadth is usually set by:
- How specifically chemical entities are defined (e.g., exact structures vs functional class)
- How strictly medical use is defined (named indication vs general class)
- Whether dosing regimens are fixed or expressed as ranges and patient stratifications
The enforceable footprint tends to be:
- Narrower when chemical structures and regimen steps are tightly defined
- Broader when Markush-style functional groups and wide dose ranges are used
What does this mean for generics and biosimilars in Finland (FTO lens)?
What do challengers usually do against this type of claim set?
In Finland-based litigation strategy, generic entry typically tests:
- Non-infringement: design out a defined salt/solvate form or adjust dosing to exit a claimed regimen range
- Invalidity: challenge novelty, inventive step, or enablement based on prior art disclosures
- Claim construction: narrow interpretation of therapeutic-use scope and regimen steps
Landscape-wise, the key decision point is whether FI3263110 sits as a core compound patent (harder to design around) or mainly as a narrow-use lifecycle patent (more design-around possible).
Patent landscape implications: family-level reading (Finland is rarely isolated)
Why the family drives Finland outcomes
A Finland national patent’s market impact is dominated by:
- Whether other members of the same priority family exist in major European markets
- Whether courts in other jurisdictions have interpreted equivalent claims
- Whether the active ingredient in question received SPC coverage in Finland
For an investor or R&D program, the actionable approach is to treat FI3263110 as one node in a network defined by:
- Priority chain
- Equivalent claim sets across jurisdictions
- Expiration timing synchronization across the family
Key Takeaways
- FI3263110 is a Finnish drug patent application/publication whose claims are structured around medicinal product and therapeutic use coverage typical of European utility drug filings.
- Enforceable scope most often concentrates on independent composition/compound claims and independent medical-use or method-of-treatment claims, with dependent claims defining narrow design-around boundaries.
- Finland market risk is driven by the family-level patent stack (priority chain, related jurisdictions, and SPC status), not only the FI publication number.
- For FTO and entry timing, the practical focus is whether a competitor’s product falls inside the defined chemical entity and/or the claimed indication and regimen.
FAQs
How do I determine whether FI3263110 is a core patent or a lifecycle patent?
Read the claim set emphasis: broad compound/composition claims indicate core coverage; narrow indication, regimen, or formulation claims indicate lifecycle coverage.
What claim category most often blocks generic entry in Finland?
Medical-use and method-of-treatment claims frequently block entry when the generic product is used in the same indication or dosing regimen, even if formulation differs.
Can design-around work against compound vs use claims?
Design-around is often harder against compound/composition claims but can be feasible against regimen or patient-subset medical-use claims when the prescribing practice avoids the claimed method steps.
Does an SPC override or extend FI utility protection?
SPCs can extend effective market exclusivity for the active ingredient in Finland even when utility patent term is closer to expiry, depending on eligibility and grant status.
What is the single most important landscape input besides FI3263110 itself?
The patent family’s priority chain and equivalent claims across jurisdictions, because Finland enforcement and expiration are synchronized by family events.
References (APA)
[1] Finnish Patent and Registration Office (PRH). Patent search results for FI3263110. https://www.prh.fi/en/patents/
[2] European Patent Office. Espacenet database for FI3263110 and related family documents. https://worldwide.espacenet.com/
